A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.
Documented active diagnosis of colorectal cancer.
Cachexia defined by Fearon criteria of weight loss.
Signed informed consent.
Current active reversible causes of decreased food intake.
Receiving tube feedings or parenteral nutrition at the time of Screening or Randomization.
Have cachexia caused by other reasons.
Parallel
NGM120 Q4W
DrugNGM120 given subcutaneously every 4 weeks
NGM120 Q8W
DrugNGM120 given subcutaneously every 8 weeks
Placebo given
DrugPlacebo given subcutaneously every 4 weeks
Change from baseline in body weight at Week 12
To evaluate the effect of NGM120 compared to placebo on body weight.
Treatment-emergent adverse events (TEAEs) characterized by type, frequency, severity, timing, seriousness, and relationship to study drug
To evaluate safety and tolerability of NGM120
Click on the lead sponsor to view all of their trials.
